A woman who was prescribed medications for off-label uses doesn’t have standing to sue the drug company that marketed them, the U.S. Court of Appeals for the Third Circuit held.
Angela Montgomery failed to show that her doctor prescribed the medicine, Rebetol, because of Schering-Plough’s marketing strategy, the Third Circuit held in its 35-page opinion in In re Schering-Plough . The New Jersey-based drug company pleaded guilty in 2007 to criminal charges related to its marketing of the drug and agreed to a $435 million settlement with the government. Montgomery’s suit was one of many civil suits that followed and was consolidated into a class action to be transferred to Schering’s home state.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
